PharmaResearch Co., Ltd.

KOSDAQ:A214450 Stock Report

Market Cap: ₩1.4t

PharmaResearch Dividend

Dividend criteria checks 2/6

PharmaResearch is a dividend paying company with a current yield of 0.68% that is well covered by earnings.

Key information

0.7%

Dividend yield

13%

Payout ratio

Industry average yield0.5%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share₩7.48k
Dividend yield forecast in 3Y0.6%

Recent dividend updates

Recent updates

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09
PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05
Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17
Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02
Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07
Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23
Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25
Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, A214450 has been paying a dividend for less than 10 years.

Growing Dividend: A214450's dividend payments have increased, but the company has only paid a dividend for 7 years.


Dividend Yield vs Market

PharmaResearch Dividend Yield vs Market
How does A214450 dividend yield compare to the market?
SegmentDividend Yield
Company (A214450)0.7%
Market Bottom 25% (KR)1.0%
Market Top 25% (KR)3.5%
Industry Average (Biotechs)0.5%
Analyst forecast in 3 Years (A214450)0.6%

Notable Dividend: A214450's dividend (0.68%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (1%).

High Dividend: A214450's dividend (0.68%) is low compared to the top 25% of dividend payers in the KR market (3.52%).


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (12.5%), A214450's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (18.6%), A214450's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.